GET DAILY SIGNALSRecursion Pharmaceuticals (RXRX): $8 Target Implies +92% Upside
Key Takeaways
- The central price target is $8, the arithmetic mean of five verified analyst price targets, rounded from $8.06.
- The latest verified closing price is about $4.16, so reaching $8 would require a roughly 92% gain — a very large move.
- The analyst target range is wide, from a low of $5.30 to a high of $11.00, reflecting sharp disagreement about the company's clinical and commercial prospects.
- Bullish support centers on AI-driven drug discovery, positive early data for REC-4881, and backing from Nvidia.
- The biggest risks are declining revenue, ongoing losses, share dilution, and heavy dependence on still-unproven pipeline programs.
Understanding the Analyst Consensus
The $8 central target comes from averaging five current, individually attributable analyst price targets. The most recent ones include Morgan Stanley at $5.30 (Equal-Weight, August 2026), Bank of America Securities at $6.00 (Neutral, February 2026), Needham at $8.00 (Buy, May 2026), J.P. Morgan at $10.00 (Overweight, April 2026), and UBS at $11.00 (December 2025). These add up to a mean of $8.06, which rounds to $8.
The spread from $5.30 to $11.00 is notably wide and points to real differences in outlook. More cautious voices like Morgan Stanley focus on execution challenges, cash burn, and the uncertain path to commercialization. Bullish voices, including Needham and J.P. Morgan, see greater value in the AI-enabled discovery platform and early clinical results. Revisions during 2026 have leaned slightly lower overall, with J.P. Morgan moving from $11 to $10 and Bank of America from $7 to $6, while Needham stayed at $8.
Current Position and Path to the Target
Recursion Pharmaceuticals, Inc. (RXRX) is a clinical-stage biotech firm that applies machine learning to speed up drug discovery. The stock recently closed near $4.16, inside a 52-week range of about $2.77 to $7.18. Hitting $8 would mean a move of roughly 92 percent and would also take it above the prior 52-week high.
That kind of advance would most likely come from more positive clinical data, progress toward regulatory talks on the lead candidate, and continued interest in AI-focused biotech names. The company shared encouraging Phase 1b/2 results for REC-4881 in familial adenomatous polyposis (FAP) and plans to discuss a potential registration path with the FDA. At the same time, revenue is expected to drop in 2026 and the firm remains unprofitable, so any sustained move higher would need to rely on pipeline progress rather than near-term financial results.
Factors That Could Support Higher Valuation
A few elements stand out as potential supports. Positive early data on REC-4881 sits at the center of the bullish case; J.P. Morgan has pointed to “blockbuster potential” with peak U.S. sales above $1 billion and an estimated 60 percent probability of success. REC-617, an oral CDK7 inhibitor for platinum-resistant ovarian cancer, provides another clinical catalyst. The partnership approach has already brought in more than $500 million in milestone payments, and the relationship with Nvidia adds credibility to the AI platform story. Broader sentiment around AI in healthcare could add further lift.
Key Risks to Consider
The main hurdles remain both financial and clinical. Revenue is projected to decline sharply in 2026, and the company continues to report sizable net losses along with negative EPS. At-the-market equity offerings raise the possibility of additional share dilution. There is no assurance that REC-4881 or REC-617 will succeed in later trials or gain regulatory approval, and commercial timelines stay uncertain. The broad spread in analyst targets, with several below $6, shows that many professionals do not see the stock approaching $8 anytime soon.
Technical Levels and Market Structure
The stock has moved up from its May 2026 low near $2.77 and sits above both the 50-day and 200-day moving averages, suggesting better near-term momentum. Resistance appears around the 52-week high of $7.18, with the $8 level just above that. Support on the downside looks to be in the $3.50-to-$3.65 area, while the 52-week low near $2.77 offers a deeper cushion. Because $8 sits just above the previous high, it would represent a breakout rather than a return to familiar territory. I also checked this setup using Tickeron’s AI tools to compare momentum across similar names.
What Investors Should Monitor
Analyst targets generally look out about 12 months, though individual assumptions can vary. It makes sense to keep an eye on upcoming earnings and guidance, any further analyst changes, FDA interactions on REC-4881’s registration path, and additional clinical updates for both REC-4881 and REC-617. Funding moves, including at-the-market offerings, matter because of their effect on share count and valuation.
Using AI Daily Buy/Sell Signals for Monitoring
One resource I turn to for tracking shifts in momentum on volatile, catalyst-driven names like this is AI Daily Buy/Sell Signals. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on evolving market conditions and technical behavior. For a stock like RXRX, it can help highlight trend changes more quickly than manual review alone, supporting decisions around entries, exits, and ongoing position management.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
RXRX's RSI Oscillator peaks and leaves overbought zone
The 10-day RSI Oscillator for RXRX moved out of overbought territory on October 06, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 instances where the indicator moved out of the overbought zone. In 25 of the 27 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 57 cases where RXRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for RXRX turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 38 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RXRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
RXRX broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on RXRX as a result. In 83 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
RXRX moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for RXRX moved above the 200-day moving average on October 12, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +14.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where RXRX advanced for three days, in 207 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 108 of 131 cases where RXRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.274) is normal, around the industry mean (2.904). P/E Ratio (-3.880) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (30.030) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. RXRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement